Clinical trials: Prostatic Adenocarcinoma
Prostate Cancer, Prostate Adenocarcinoma
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
This study is trying to find out if the combination of Androgen deprivation therapy (ADT), MRI guided high dose radiation (HDR) brachytherapy treatment (internal radiation implant procedure) and external beam radiation therapy…
- Trial name
- Prostate005 (NCT04465500)
- Testing
- External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Virginia
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT03456804
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostatic Adenocarcinoma
Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer
Gold markers implanted in the prostate are used frequently for position verification of the prostate during external-beam radiotherapy.
- Trial name
- NCT03384199
- Testing
- Dose escalation to prostate focal lesion
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Kasr El Aini Hospital
Prostate Cancer
Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery
RATIONALE: Green tea contains ingredients that may prevent or slow the growth of certain cancers. It is not yet known whether green tea is more effective than black tea or water in treating prostate cancer.
- Trial name
- NCT00685516
- Testing
- green tea, decaffeinated black tea
- Where
- 2 sites in United States
- Volunteers
- 113 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Radiotherapy - Adjuvant Versus Early Salvage
Radical prostatectomy (RP) is the most common curative approach offered to men with newly diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors placing them at high risk of their cancer…
- Trial name
- RAVES (NCT00860652)
- Testing
- Adjuvant Radiotherapy, Early Salvage Radiotherapy
- Where
- 36 sites in Australia, New Zealand
- Volunteers
- 333 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Trial name
- ProvONE (NCT06134232)
- Testing
- Sipuleucel-T Injection
- Where
- 31 sites in United States
- Volunteers
- 400 people
- Sponsor
- Dendreon
Prostate Cancer
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003614
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 28 sites in United States, South Africa
- Sponsor
- Eastern Cooperative Oncology Group
Prostate Cancer Metastatic
Dynamic 68Ga-PSMA and 18F-FDG PET/CT Analysis Prior to 177Lu-PSMA
Prostate cancer is a significant health issue, representing 21.8% of male cancer cases in France with over 449,000 new cases in 2018. It's the cause of 10% of cancer deaths in Europe.
- Trial name
- PYPET (NCT06450548)
- Testing
- Parametric acquisition
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Henri Becquerel
Prostate Adenocarcinoma
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread…
- Trial name
- NCT05050084
- Testing
- Bicalutamide, Buserelin, Darolutamide
- Where
- 576 sites in United States, Canada
- Volunteers
- 2,050 people
- Sponsor
- NRG Oncology
Prostate Cancer (Adenocarcinoma), Prostate Cancer After a Radical Treatment
Genetic Studies of Prostate Cancer Aggressiveness and Prognosis
Prostate cancer is the most common form of cancer and the leading cause of cancer-related deaths among men in Sweden. In 2021, over 10,000 men were diagnosed with prostate cancer, and 2,077 died from the disease.
- Trial name
- NCT06773858
- Where
- Sweden
- Volunteers
- 2,291 people
- Sponsor
- Karolinska Institutet
Adenocarcinoma of the Prostate, Bone Metastases
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01807065
- Testing
- sipuleucel-T, external beam radiation therapy, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- City of Hope Medical Center
Prostate Cancer
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did…
- Trial name
- NRR (NCT00246753)
- Testing
- lapatinib ditosylate
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adenocarcinoma of Prostate
HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.
Investigators compare in a randomized clinical trial the results and side effects of high-dose- and low-dose-rate brachytherapy as monotherapy in the treatment of early, organ confined prostate cancer patients.
- Trial name
- PROMOBRA (NCT02258087)
- Testing
- LDR Brachytherapy, HDR Brachytherapy
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- National Institute of Oncology, Hungary
Prostate Cancer
MRI in Assessing Hypoxia in Patients With Localized Prostate Cancer Undergoing Stereotactic Body Radiation Therapy
RATIONALE: Diagnostic procedures, such as MRI, may help measure oxygen levels in tumor cells. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00963300
- Testing
- blood-oxygen-level-dependent functional magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, magnetic resonance spectroscopic imaging
- Sponsor
- University of Texas Southwestern Medical Center
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC)
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
- Trial name
- NCT06943521
- Testing
- MT-4561
- Where
- 6 sites in United States, Japan
- Volunteers
- 27 people
- Sponsor
- Tanabe Pharma America, Inc.
Prostate Cancer Adenocarcinoma, Erectile Dysfunction Following Radical Prostatectomy
Use of Indocyanine Green in Robotic Prostate Surgeries
Imaging of the vascular nerve bundle using Indocyanine Green
- Trial name
- NCT05960149
- Testing
- using Indocyanine Green, Nerve-sparing robot-assisted laparoscopic radical prostatectomy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ankara University
Prostate Cancer
SB939 in Treating Patients With Recurrent or Metastatic Prostate Cancer
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well SB939 works in treating patients with recurrent or metastatic prostate…
- Trial name
- NCT01075308
- Testing
- HDAC inhibitor SB939
- Where
- 7 sites in Canada
- Volunteers
- 32 people
- Sponsor
- NCIC Clinical Trials Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.